{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(17)"],"submitter":["Rajan K"],"pubmed_abstract":["<h4>Introduction and aims</h4>Androgen deprivation therapy (ADT) with systemic anti-cancer treatment (SACT) ± palliative radiotherapy (pRT) is the current standard of care for Oligo-metastatic hormone-sensitive prostate cancer (o-mHSPC). Cytoreductive radical prostatectomy (cRP) has gained interest in this group of patients, with potential benefits including reduced tumour burden and a lower risk of local events from disease progression. In this review, we compare both survival outcomes and local event rates between cRP and upfront ADT ± SACT.<h4>Methods</h4>All randomised trials and observational studies comparing cRP with standard treatment (ST), which we defined as ADT ± SACT for o-mHSPC, were included in the review. The study protocol was registered in PROSPERO (CRD42024516586), and th"],"journal":["Cancers"],"pagination":["2757"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12427360"],"repository":["biostudies-literature"],"pubmed_title":["Role of Radical Prostatectomy in Oligo-Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Meta-Analysis."],"pmcid":["PMC12427360"],"pubmed_authors":["Rai BP","Geraghty R","Parmar K","Rajan K","Whyte E","Rajamoorthy SI"],"additional_accession":[]},"is_claimable":false,"name":"Role of Radical Prostatectomy in Oligo-Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Meta-Analysis.","description":"<h4>Introduction and aims</h4>Androgen deprivation therapy (ADT) with systemic anti-cancer treatment (SACT) ± palliative radiotherapy (pRT) is the current standard of care for Oligo-metastatic hormone-sensitive prostate cancer (o-mHSPC). Cytoreductive radical prostatectomy (cRP) has gained interest in this group of patients, with potential benefits including reduced tumour burden and a lower risk of local events from disease progression. In this review, we compare both survival outcomes and local event rates between cRP and upfront ADT ± SACT.<h4>Methods</h4>All randomised trials and observational studies comparing cRP with standard treatment (ST), which we defined as ADT ± SACT for o-mHSPC, were included in the review. The study protocol was registered in PROSPERO (CRD42024516586), and th","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-04-08T19:16:00.724Z","creation":"2026-04-08T12:10:18.468Z"},"accession":"S-EPMC12427360","cross_references":{"pubmed":["40940854"],"doi":["10.3390/cancers17172757"]}}